BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid off via a takeout by Merck for $425 million up front. Under the deal, which includes undisclosed milestones and royalties, Merck & Co. Inc....
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

In an award ceremony recognizing eight achievements in the life sciences in China this year, BayHelix highlighted the rapid growth of financing and deals by China’s biopharma companies. Innovent took home the Company of the Year...
BioCentury | Nov 17, 2020
Deals

Nov. 16 Quick Takes: Roche-Lead in immunology deal; plus TNBC approval for Keytruda and Apellis, BMS, BeyondSpring, Start Codon, Myricx and PureTech

Roche, Lead Pharma form immunology partnershipDutch biotech Lead Pharma Holding B.V. will collaborate with Roche (SIX:ROG; OTCQX:RHHBY) to develop preclinical small molecules against a single, undisclosed target to treat immune-mediated diseases. Lead will receive €10 million...
BioCentury | Nov 14, 2020
Deals

Innovation in a hurry: China biotechs see a fast track to global stage – survey

The Chinese biopharma landscape in five years will see a majority of the money magnet companies commanding innovation, with first-in-class targets filling their pipelines and innovative biologics outpacing...
BioCentury | Nov 11, 2020
Emerging Company Profile

CatalYm: opening up tumors to immune cells

CatalYm is targeting a lesser known immunosuppressant function of GDF15 to resensitize cancer patients to checkpoint blockade and enhance the ability of CAR T therapies to infiltrate solid tumors. The Munich-based biotech has raised €50 million...
BioCentury | Nov 11, 2020
Product Development

Nov. 10 Quick Takes: Tezepelumab meets in asthma Phase III; plus a call for speedy trial results, updates on COVID vaccines from Sinovac, CureVac and more

AZ, Amgen rise on asthma dataTezepelumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) met the primary endpoint of a statistically significant reduction in annualized asthma exacerbation...
BioCentury | Nov 10, 2020
Product Development

First biomarker data from pioneering tau program in Alzheimer’s cloud use of antibodies for the target

Data presented at the annual CTAD meeting hint that anti-tau therapy semorinemab from Genentech and AC Immune may have engaged its target yet failed to decrease tau aggregation in a Phase II study to treat...
BioCentury | Nov 7, 2020
Finance

Apollomics anchors investor base in Asia with $124M raise as it readies for its next phase of growth

Apollomics has shored up its Asian investor base with a $124 million series C round that provides the oncology company with flexibility to advance its pair of lead compounds while continuing to hunt for...
Items per page:
1 - 10 of 4824